Search

Displaying results 2901 - 2910 of 4590 in total
  1. Drug

    Benzoic acid

    go.drugbank.com/drugs/DB03793
    ApprovedInvestigational

    Total Positive and Negative Syndrome Scale scores dropped by 21% compared to placebo.

  2. Drug

    VIT-100

    go.drugbank.com/drugs/DB05865
    Experimental

    VIT-100 was developed by ItherX Pharmaceuticals of San Diego.

  3. Drug

    Bosutinib

    go.drugbank.com/drugs/DB06616
    ApprovedInvestigational

    [L48436] On September 26, 2023, bosutinib was also approved by the FDA for the treatment of pediatric CML that is newly diagnosed or resistant/intolerant to prior therapy. … [A6901,A17961] Bosutinib was first approved by the FDA in 2012 for the treatment of adult chronic, accelerated, or blast-phase Ph+ CML with resistance or intolerance to prior therapy.

  4. Drug

    Citraconic acid

    go.drugbank.com/drugs/DB04734
    Experimental

    Citraconic acid is one of the isomeric dicarboxylic acids produced by the distillation of citric acid, or as metabolites by microorganisms, cis-CH3-C(CO2H)=CHCO2H; the trans-isomer is mesaconic acid.

  5. Drug

    Iocarmic acid

    go.drugbank.com/drugs/DB13755
    Experimental

    Categories: Watersoluble, Nephrotropic, High Osmolar X-Ray Contrast Media
  6. Drug

    PlasmaCord

    go.drugbank.com/drugs/DB16363
    Experimental

    PlasmaCord is platelet-poor plasma that is derived by fractionation from sterile umbilical cord and placental blood. … [L27581] It is developed by Cellpraxis and is currently being investigated against severe acute respiratory syndrome (SARS).

  7. Drug

    CERE-110

    go.drugbank.com/drugs/DB05898
    Investigational

    This drug is developed by Ceregene and currently under phase I of clinical trial.

  8. Drug

    105AD7

    go.drugbank.com/drugs/DB05113
    Investigational

    105AD7 is a human monoclonal antibody that mimics the complement regulatory protein, CD55, overexpressed by many solid tumours including osteosarcoma. 105AD7 induced antitumour inflammatory responses in

  9. Drug

    Beclamide

    go.drugbank.com/drugs/DB09011
    Experimental

    It was studied in the 1950s for generalised tonic-clonic seizures but was not effective for absence seizures.

  10. Drug

    Tezosentan

    go.drugbank.com/drugs/DB06558
    Investigational

    Tezosentan was initially developed for vasodilation in patients with acute heart failure but studies have shown that it does not assist in the treatment of dyspnea or prevent cardiovascular events.